Topical Treatment for TMJ Arthralgia

NCT ID: NCT05816226

Last Updated: 2024-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:

* How does pain reduction compare?
* How does improvement in jaw function limitation compare?
* How do side effects compare? Participants will
* On day 1 be examined and report their pain level and jaw function limitation
* On days 1-21, apply their cream four times a day
* On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.

Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Person 2 will label creams, patient packets (pre-stamped envelope, questionnaire, consent form), and give packets to Person 1 in the order in which they are to be dispensed.
* Person 1 will recruit all eligible patients in the order in which they are seen, enrolling all that consent. Packets and gel will be given to patient, and written and verbal instructions, including that email will be sent saying "Keep it up!" to remind them to continue applying get, as well as "Please send us your questionnaire". Consent forms will be stored in locked drawer.
* Person 1 will remind patient on days 7 and 14 to continue with the study
* Person 1 will remind patient on day 21 to mail back the completed questionnaire
* Person 1 will reach out to all patients from whom the questionnaire is not returned within 1 week of day 21, and do so at weekly intervals a minimum of 3 times.
* Person 1 will enter data in Excel as it comes, reaching out to patients if there are questions. Excel file uses random number ID, not patient name, thereby anonymizing the data
* Persons 1, 2, 3, and 4 will decide which patient's data, if any, should be removed
* Person 1 will send complete anonymized Excel data file (containing all patients) to Person 3
* Person 2 will determine, using random number generator, which group will be referred to as "Group A" during the statistical analysis, and which will be referred to as "Group B"
* Person 2 will tell Dr. Korczeniewska which data will be in Group A, and which will be in Group B
* Person 3 will perform statistical analysis
* Person 2 will reveal which group was Hydrocortisone, and which was Diclofenac

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TMJ Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

diclofenac hydrocortisone TMJ arthralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Cream containers labeled by randomly-generated numbers, by person not involved in analysis or patient interaction.

Statistical analysis done by person not aware of the treatment received by each group

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrocortisone topical

2.5% hydrocortisone cream

Group Type EXPERIMENTAL

Hydrocortisone 2.5%

Intervention Type DRUG

Applied four times daily to TMJ with arthralgia

Diclofenac topical

1% diclofenac cream

Group Type ACTIVE_COMPARATOR

Diclofenac 1% topical

Intervention Type DRUG

Applied four times daily to TMJ with arthralgia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocortisone 2.5%

Applied four times daily to TMJ with arthralgia

Intervention Type DRUG

Diclofenac 1% topical

Applied four times daily to TMJ with arthralgia

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Arthralgia of at least 1 TMJ for at least 3 days

Exclusion Criteria

* Systemic pain condition
* Past adverse reaction to steroid
* Currently taking steroid
* Taken steroid in the past \_\_\_ months
* Muscle relaxants (may start after study is complete)
* New night guard during study, or within 1 month of start of study (may start after study is complete)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of the Pacific

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andrew Young

Assistant Professor, Department of Diagnostic Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arthur A. Dugoni School of Dentistry, University of the Pacific

San Francisco, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andrew Young, DDS, MSD

Role: CONTACT

Phone: 4153517126

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andrew Young, DDS, MSD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Bariguian Revel F, Fayet M, Hagen M. Topical Diclofenac, an Efficacious Treatment for Osteoarthritis: A Narrative Review. Rheumatol Ther. 2020 Jun;7(2):217-236. doi: 10.1007/s40744-020-00196-6. Epub 2020 Feb 21.

Reference Type BACKGROUND
PMID: 32086778 (View on PubMed)

Wade AG, Crawford GM, Young D, Corson S, Brown C. Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries. J Int Med Res. 2019 Sep;47(9):4454-4468. doi: 10.1177/0300060519859146. Epub 2019 Jul 29.

Reference Type BACKGROUND
PMID: 31353997 (View on PubMed)

Niethard FU, Gold MS, Solomon GS, Liu JM, Unkauf M, Albrecht HH, Elkik F. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005 Dec;32(12):2384-92.

Reference Type BACKGROUND
PMID: 16331769 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023 Young A 1

Identifier Type: -

Identifier Source: org_study_id